Advancements in Alzheimer's Disease: Emerging Therapies, Lifestyle Modifications, and Early Intervention Strategies

Theprit Sitthiyod
Samakkhiwitthayakhom School, Wiang Subdistrict, Mueang Chiang Rai District, Chiang Rai 57000, Thailand

ABSTRACT: Alzheimer’s disease (AD), the most prevalent form of dementia, represents a major global health challenge, affecting over 45 million people worldwide with projections to triple by 2050 [1]. This progressive, irreversible neurodegenerative disease leads to cognitive decline, behavioural changes, and a significant socioeconomic burden [2]. Despite extensive research into its complex pathophysiology, involving beta-amyloid plaques and tau protein tangles, the exact causes remain a mix of genetic, environmental, and lifestyle factors [3]. Current treatments primarily focus on symptom management, as no cure exists [4]. This literature review synthesises recent advancements in Alzheimer’s research, exploring new pharmacological treatments, emerging therapies, and the efficacy of prevention strategies. It particularly examines how lifestyle modifications and risk factor management influence disease progression. The review highlights the potential of early intervention in at-risk individuals, aiming to prevent significant neural damage before clinical symptoms appear. It discusses the impact of various lifestyle factors such as diet, exercise, mental and social engagement, and cardiovascular health on AD risk. Understanding these connections is crucial, given the ageing population and rising prevalence of AD. This review aims to inform better clinical practices and health policies, potentially reducing Alzheimer’s impact and guiding healthcare professionals, researchers, and policymakers in effective interventions. Ultimately, these insights could substantially alleviate the socioeconomic burden of Alzheimer’s disease and improve public health outcomes.

KEYWORDS: Alzheimer's disease, Beta-amyloid plaques, Neurodegenerative disorders.

INTRODUCTION

Alzheimer’s disease (AD), the most common form of dementia, accounts for 60–80% of cases and significantly contributes to the global public health challenge posed by dementia [5]. The prevalence of dementia worldwide is currently estimated at over 45 million people and is predicted to triple by 2050, primarily due to increased life expectancy [6]. AD is a progressive, irreversible neurodegenerative disease that not only leads to cognitive decline and behavioral changes but also imposes a substantial socioeconomic burden [2]. Despite extensive research into its complex pathophysiology, which involves the accumulation of beta-amyloid plaques and tau protein tangles, the exact causes of Alzheimer's remain a mix of genetic, environmental, and lifestyle factors [3]. Currently, there is no cure for Alzheimer’s, and treatments are mainly focused on symptom management and improving the quality of life [4]. This literature review aims to synthesize the latest advancements in Alzheimer's research, exploring new pharmacological treatments and emerging therapies, evaluating the efficacy of prevention strategies that include lifestyle modifications and risk factor management, and investigating how lifestyle factors influence the progression of the disease. The significance of this review is underscored by the urgent need to address the escalating prevalence of Alzheimer’s and the absence of definitive treatments [7]. By understanding the effectiveness of new therapies and preventative strategies, this review seeks to guide better clinical practices and health policies, potentially reducing the impact of Alzheimer's and aiding healthcare professionals, researchers, and policymakers in making informed decisions to combat this challenging condition effectively [8]. Determining whether late-life risk factors are causal or only coincide with pathological changes is difficult since Alzheimer's disease (AD) develops during a lengthy preclinical period that can last decades [3]. Understanding the connection between early/mid-life exposures and the emergence of AD later in life has been made possible by longitudinal research involving people in their early to mid-life [3]. Numerous modifiable risk factors linked to AD have been found through observational studies [2]. Diabetes mellitus, smoking, depression, inactivity both mentally and physically, poor food, high blood pressure, obesity, and low educational attainment are a few of these [2]. Recent research has connected midlife vascular risk factors to amyloid deposition later in life, suggesting that risk factor treatment may be able to prevent up to one-third of instances of AD [2]. AD risk is associated with a
number of lifestyle factors, including food, physical exercise, smoking, and mental/social involvement, as well as cardiovascular risk factors like diabetes, hypertension, and obesity [2]. Amyloid beta (Aβ) buildup in the brain may be influenced by diabetes, whereas hypertension may disrupt the blood-brain barrier, resulting in cell injury and Aβ accumulation [2]. Body weight and AD risk appear to be related in a complicated way, with midlife obesity perhaps raising the risk [2]. Although oxidative stress and inflammatory reactions are linked, the relationship between smoking and the risk of AD is still under discussion [2]. It's possible that mechanisms including brain plasticity, vascularization, and decreased inflammation are responsible for the beneficial effects of physical activity [2]. Through processes including the improvement of cognitive reserve, the Mediterranean diet and intellectual, social, and cognitive activities are associated with a decreased risk of AD [2]. By increasing cognitive reserve, better education and mentally challenging activities reduce the incidence of dementia and cognitive decline [2]. Additionally, delayed dementia development has been associated with bilingualism, indicating a preventive impact against neurodegeneration [2]. Therapeutic approaches are still desperately needed for the remaining instances of AD, even if addressing modifiable risk factors shows promise for averting a sizable majority of cases [2]. The purpose of this review is to determine whether lifestyle changes like diet, exercise, avoiding injuries, and cognitive stimulation can delay or prevent the onset of Alzheimer's disease. It will also evaluate the ways in which these factors, in addition to genetic predispositions and other medical conditions, contribute to Alzheimer's disease [7]. Understanding the impact of lifestyle decisions on Alzheimer's disease is critical, especially considering the aging population and its widespread prevalence [2]. This research is significant as it delves into prospective preventative measures, shedding light on the efficacy of lifestyle modifications such as diet, exercise, injury prevention, and cognitive stimulation in delaying or preventing the onset of Alzheimer's disease [7]. By assessing how these factors, alongside genetic predispositions and other health conditions, contribute to the disease, the review aims to inform individuals and policymakers about effective interventions [2]. Ultimately, such insights could substantially reduce the socioeconomic burden of Alzheimer's disease and improve public health outcomes [2].

Pharmacological Treatments
The diagnostic criteria for Alzheimer's disease (AD), the most prevalent type of dementia and a leading neurodegenerative disorder among the elderly, have been extensively updated. It accounts for approximately 90% of dementia cases in older adults and is marked by irreversible progression and loss of function, cognition, and behavior, often associated with brain disorders like amnesia, agnosia, apraxia, and aphasia. Experts agree that the primary pathological indicators of AD include elevated levels of amyloid-beta peptide, which accumulates extracellularly in plaques, and hyperphosphorylated tau protein, which forms tangles within cells. Traditionally, AD diagnosis focused on patients already in the dementia stage, but there is now a growing understanding of a critical pre-dementia phase that begins symptom-free, known as preclinical AD, which can start around 20 years before any symptoms appear [9].

Despite these insights, no treatments tested in clinical trials have effectively changed the course of AD dementia. Therefore, much of the current research has shifted towards early intervention in cognitively healthy individuals who are at risk of developing AD. This strategy focuses on preventing significant, irreversible damage to neuronal networks before the emergence of overt clinical symptoms, with the aim of reducing the incidence and prevalence of the disease. Several strategies have been developed to reduce the amyloid burden in Alzheimer's disease, focusing on different stages of the disease's progression. Amyloid-beta (Aβ) is produced from the precursor protein APP through the action of enzymes gamma-secretase and beta-secretase, which have become targets for new drug development. Additionally, enzymes like neprilysin that degrade Aβ are also considered in drug development efforts. Another approach includes immunotherapy to remove Aβ.

In 2019, there were nine phase 3 trials involving eight drugs targeting amyloid, indicating a shift towards earlier intervention. Two trials specifically targeted patients with preclinical AD—one requiring a positive amyloid PET scan and the other requiring genetic markers of risk. Four trials targeted patients with prodromal AD, all of whom had positive biomarkers for early AD. The trials variously included patients with mild cognitive impairment (MCI) due to AD or mild dementia due to AD, without including those in advanced stages of AD, reflecting a consensus that anti-amyloid therapy is less effective later in the disease. Compared to previous years, the number of such trials decreased in 2019, with a strategic focus on early stages of the disease. Biomarkers such as CSF amyloid and tau levels, volumetric MRI, and amyloid PET scans are frequently used as secondary outcomes in these trials. The Alzheimer's Disease Composite Score (ADCOMS) is used to measure cognitive outcomes, particularly useful in early-stage AD trials where cognitive deficits are limited [10].
Non-Pharmacological Therapies:

Dementia, particularly Alzheimer's disease (AD), is a major global health challenge. AD is not an unavoidable result of aging, and several lifestyle factors, including physical activity, can impact the risk of developing it. Low physical activity levels are associated with a higher risk of AD. Exercise, encompassing both aerobic and resistance training, can be an effective strategy for the treatment and prevention of AD. Older adults who engage in regular exercise are more likely to preserve their cognitive abilities. This review examines how exercise protects brain function, focusing on aspects such as amyloid β turnover, reduction of inflammation, neurotrophin production and release, and improved blood flow to the brain. Encouraging lifestyle changes, particularly before symptoms appear, could potentially delay up to one-third of dementia cases worldwide. Thus, it is recommended that older adults adopt an active lifestyle through comprehensive interventions [1].

In the twenty-first century, dementia, especially Alzheimer's disease (AD), is a significant global health concern. AD is not a natural aspect of aging, and risk factors related to lifestyle choices, particularly physical exercise, are important. Reduced physical activity is a recognized AD risk factor. This study examines the benefits of exercise, particularly resistance and aerobic training, in the treatment and prevention of AD. In older persons, regular exercise is associated with improved cognitive performance. Based on studies on humans and animals, the review looks at how exercise affects amyloid β turnover, reduced inflammation, synthesis of neurotrophin, and better cerebral blood flow in relation to brain health. Early lifestyle promotion can avert up to one-third of dementia cases worldwide, therefore these kinds of interventions are crucial for senior citizens [1].

The aging population is causing Alzheimer's disease (AD) to become a significant healthcare challenge without a cure. Given disappointing results from trials for mild to moderate AD and clear evidence of risk factors, efforts are shifting towards prevention. Understanding the lengthy asymptomatic phase of AD enables interventions before irreversible damage occurs, which is crucial [2]. Mild Alzheimer’s disease is the main cause of dementia, making up 50–70% of cases, and it significantly disrupts daily activities and social interactions. As life expectancy rises and populations age, particularly in developing countries, the prevalence of Alzheimer’s disease is expected to increase, leading to substantial healthcare costs. Alzheimer’s is a complex disorder influenced by genetic and environmental factors throughout a person's life. Studies have identified modifiable risk and protective factors that could help prevent Alzheimer’s. Since the disease can begin decades before symptoms appear, targeting these risk factors in middle-aged and elderly individuals may help delay or prevent its onset. This overview covers recent epidemiological findings on modifiable risk factors and highlights the importance of early preventive measures [3].

Mild Alzheimer’s disease, responsible for 50–70% of dementia cases, is an irreversible neurodegenerative condition that impairs daily activities and social interactions. As life expectancy increases and populations age, particularly in developing countries, the prevalence of Alzheimer’s is projected to rise, leading to significant healthcare costs. Alzheimer’s is a complex disorder influenced by both genetic and environmental factors throughout life. Epidemiological research has identified modifiable risk and protective factors that could help prevent the disease. Since Alzheimer’s often begins decades before symptoms appear, addressing these risk factors in middle-aged and elderly individuals may help delay or prevent its onset. This overview focuses on recent epidemiological findings regarding these modifiable risk factors and underscores the importance of early preventive measures [3].

Interpreting evidence on preventing Alzheimer’s disease (AD) is difficult due to varying study designs and credibility. This systematic review and meta-analysis aimed to offer evidence-based prevention suggestions by analyzing prospective studies. Databases and websites were searched up to March 1, 2019, including both observational prospective studies (OPSs) and randomized controlled trials (RCTs). Out of 44,676 reports, 243 OPSs and 153 RCTs met the criteria, covering 104 modifiable factors and 11 interventions. The analysis produced 21 suggestions: 19 Class I suggestions supported by strong (Level A) or weaker (Level B) evidence. Level A evidence backs factors like education, cognitive activity, and midlife hypertension, while Level B supports factors such as midlife obesity and physical exercise. Additionally, estrogen replacement therapy and acetylcholinesterase inhibitors are not recommended. This review consolidates current evidence to suggest effective AD prevention strategies and identifies interventions that should be avoided [4].

Prevention Strategies

Risk Factor Modification

Intervention strategies focusing on modifiable risk factors for dementia are emerging as significant preventive approaches. Notably, epidemiological studies indicate a decrease in the incidence of age-specific dementia, likely due to improved management of cardiovascular risks.

5745 *Corresponding Author: Theprit Sitthiyod
One prominent example is the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), which explores whether a multifaceted approach including diet, exercise, cognitive training, and vascular risk monitoring can prevent cognitive decline in older adults at risk of dementia. Early results from this large-scale randomized controlled trial (RCT) show that such interventions can maintain or improve cognitive function in older individuals. Conversely, the Prevention of Vascular Dementia by Intensive Care (PreDIVA) trial assessed whether managing cardiovascular risks could reduce dementia incidence. This trial did not find a reduction in dementia rates despite improvements in systolic blood pressure, suggesting that baseline low cardiovascular risks and high-quality usual care might dilute potential benefits.

Another study, the Multidomain Alzheimer Preventive Trial (MAPT), tested the effectiveness of nutritional counseling, physical exercise, cognitive training, and omega-3 fatty acid supplementation on preventing cognitive decline in older adults with memory complaints. After three years, the interventions showed no significant impact on cognitive decline, though post-hoc analysis indicated some benefits for participants with positive amyloid scans.

Additionally, the Healthy Ageing Through Internet Counselling in the Elderly (HATICE) study is evaluating an eHealth intervention aimed at optimizing self-management of lifestyle-related cardiovascular risk factors through a coach-supported platform, expecting to improve cardiovascular and cognitive health outcomes. These findings are foundational for the European Dementia Prevention Initiative’s Multimodal Preventive Trials for Alzheimer’s Disease (MIND-AD) project, which seeks to identify effective AD prevention strategies tailored to different at-risk groups. This project incorporates multidomain interventions and innovative delivery models, such as computer-based training and medical food, utilizing feedback from trial participants and data from several European countries to optimize strategies. A pilot study will soon test these interventions in individuals with early-stage AD.

Early Detection and Screening: Summarize the latest methods for early diagnosis and predictive screening.

Early detection and screening are pivotal in the management and treatment of Alzheimer's disease (AD), allowing for earlier intervention, which can slow the progression of symptoms and improve quality of life. This section summarizes the latest methods for early diagnosis and predictive screening of Alzheimer’s disease, highlighting both established and emerging techniques.

Biomarker Testing

Advancements in biomarker research have led to significant improvements in the early detection of Alzheimer’s disease. Biomarkers are biological indicators found in brain imaging, blood tests, and cerebrospinal fluid (CSF) that can detect changes associated with Alzheimer's before the onset of clinical symptoms. Key biomarkers include:

- Beta-amyloid proteins, which accumulate to form plaques, a hallmark of Alzheimer's disease. These can now be detected through positron emission tomography (PET) scans or in the CSF.
- Tau proteins, which form tangles within brain cells, another signature of Alzheimer’s. Tau levels are also measurable via PET scans and CSF analysis.
- Neurofilament light chain (NFL), a marker of neuronal damage and neurodegeneration, has been increasingly detected in blood tests, offering a less invasive screening option.

Neuroimaging Techniques Advanced imaging technologies such as MRI and PET scans are utilized to measure early changes in the brain that are associated with Alzheimer’s disease. These techniques can detect amyloid plaque accumulation, neurofibrillary tangles, and structural brain changes well before clinical symptoms appear [4].

Genetic Testing

Genetic testing for Alzheimer’s disease is primarily focused on identifying the presence of the apolipoprotein E (APOE) ε4 allele, the most significant genetic risk factor for the late-onset form of the disease. While genetic testing can indicate susceptibility, it does not confirm that a person will develop Alzheimer's, limiting its predictive power but providing important information for risk assessment.

Neuroimaging Techniques

Advanced imaging techniques continue to play a crucial role in early detection:

- Magnetic resonance imaging (MRI) helps in detecting brain shrinkage or atrophy, particularly in the hippocampus and entorhinal cortex, areas affected early in Alzheimer's disease.
- Fluorodeoxyglucose-PET (FDG-PET) scans measure the metabolic activity of the brain, where reduced glucose metabolism serves as an early indicator of disease.
Cognitive Testing and Assessment Tools
Routine cognitive screening through structured cognitive tests can help detect early cognitive impairment that may indicate the onset of Alzheimer's. These tests assess memory, executive function, language abilities, and other cognitive domains. Examples include the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).

Digital Tools and Artificial Intelligence
Digital Tools and Artificial Intelligence
Recent innovations include the use of digital tools and artificial intelligence (AI) to analyze data patterns that may not be evident through traditional diagnostic methods. AI algorithms can process vast amounts of medical data, including genetic information, imaging scans, and results from cognitive tests, to identify subtle patterns that predict Alzheimer's risk [5].

The landscape of early detection and screening for Alzheimer's disease is rapidly evolving, driven by technological advances and a deeper understanding of the disease's pathophysiology. The integration of biomarkers, genetic testing, advanced imaging, cognitive assessments, and innovative digital tools offers a comprehensive approach to identifying Alzheimer's disease at its earliest stages. This progress not only facilitates timely and accurate diagnosis but also opens the door for targeted interventions that could alter the disease trajectory and improve patient outcomes.

Impact of Diet and Nutrition

Mediterranean Diet and Alzheimer's Disease
A significant body of research has highlighted the Mediterranean diet as beneficial in slowing the progression of Alzheimer's disease. The diet, rich in fruits, vegetables, whole grains, olive oil, and fish, emphasizes low consumption of meat and dairy products. A systematic review by Gregory et al. (2023) found that adherence to the Mediterranean diet was associated with a reduced risk of developing AD and a slower progression in patients already diagnosed. The neuroprotective effects are attributed to high levels of antioxidants and anti-inflammatory compounds present in the diet, which combat oxidative stress and inflammation, known contributors to AD pathology [8].

Ketogenic Diet and Cognitive Function
Emerging research has also considered the ketogenic diet, which is high in fats and low in carbohydrates, in managing Alzheimer's disease. Iacovides et al. (2019) reported that a ketogenic diet could enhance cognitive function in AD patients by providing ketone bodies as alternative energy sources for the brain, potentially alleviating brain glucose hypometabolism, a hallmark of AD. However, long-term adherence and the diet's broader health impacts require further investigation [9].

Impact of Specific Nutrients
Omega-3 Fatty Acids: Omega-3 fatty acids, primarily found in fish, have been extensively studied for their role in brain health. Studies like those by Troesch et al. (2020) suggest that omega-3 fatty acids can decrease beta-amyloid plaques and tau protein tangles, characteristic of AD pathology, thus moderating disease progression [10].

Vitamins B, C, D, and E: Vitamins have also been implicated in AD management. Vitamin E, a powerful antioxidant, has been shown to slow functional decline in AD patients, as evidenced by Alam et al. (2022) [11]. Similarly, folate and vitamins B6 and B12 play crucial roles in homocysteine metabolism, whose dysregulation is associated with an increased risk of AD [12].
Curcumin: As a component of turmeric, curcumin has shown potential in reducing oxidative damage and inflammation in neuronal cells. A study by Goozee et al. (2016) suggests that curcumin can inhibit the aggregation of amyloid proteins in the brain, offering a therapeutic pathway for AD [13].

**Dietary Patterns and Risk Reduction**

Research has also examined broader dietary patterns beyond individual nutrients. The DASH (Dietary Approaches to Stop Hypertension) diet and its combination with the Mediterranean diet, forming the MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay), have been associated with lower risks of cognitive decline. Morris et al. (2015) found that high adherence to the MIND diet substantially lowered the risk of AD development. These diets emphasize nutrients that are hypothesized to be neuroprotective [14].

**Physical activities**

**Exercise and Neuroprotection**

A wealth of research supports the neuroprotective effects of regular physical activity. Exercise is believed to influence brain health through several mechanisms including the enhancement of blood flow, reduction in cardiovascular risk factors, and improvement in metabolic function. Ahlskog et al. (2011) conducted a comprehensive review suggesting that aerobic exercise can increase brain volume in regions susceptible to AD pathology, such as the hippocampus. This effect is mediated by the upregulation of brain-derived neurotrophic factor (BDNF), a molecule essential for neuronal growth and survival [15].

**Epidemiological Evidence**

Several epidemiological studies have correlated regular physical activity with a reduced risk of developing Alzheimer's disease. For instance, a longitudinal study by Lautenschlager et al. (2008) reported that older adults engaging in regular physical activity had a lower incidence of AD compared to their sedentary counterparts. The study suggests that moderate-intensity physical activities, such as walking, are sufficient to confer this protective effect [16].

**Randomized Controlled Trials (RCTs)**

Randomized controlled trials provide robust evidence of the benefits of exercise in AD. The study by Karssemeijer et al. (2017) demonstrated that a structured physical activity regimen improved cognitive function and delayed the progression of symptoms in early-stage AD patients. Participants engaged in tailored exercise programs showed significant improvements in memory and executive function tests compared to the control group [17].

**Mechanistic Insights**

**Cognitive Reserve Theory**

The concept of cognitive reserve, or the brain's resilience to neuropathologic damage, is also relevant in the context of exercise [18]. Physical activity is posited to contribute to a greater cognitive reserve, thus delaying the onset of clinical symptoms of Alzheimer's despite the presence of disease pathology [19]. This theory is supported by observational data linking higher levels of lifetime physical activity with better cognitive outcomes in older age [19].

Cognitive activities such as reading, playing musical instruments, engaging in puzzles, and other mentally stimulating tasks have been linked to a lower risk of Alzheimer's disease [20]. The underlying theory is that these activities enhance cognitive reserve—the brain's ability to improvise and find alternate ways of completing tasks when typical pathways are damaged. A notable study found that individuals who regularly engaged in complex cognitive activities had a 46% lower risk of manifesting Alzheimer's symptoms compared to those with minimal cognitive activity [3]. Furthermore, longitudinal research indicates that continued cognitive engagement may slow cognitive decline in individuals with Alzheimer's, potentially through the maintenance of neural connections and enhanced neuroplasticity [3].

Social interactions and maintaining relationships are also considered beneficial in reducing the risk of Alzheimer's disease [21]. Social engagement helps to combat isolation and depression, which are known risk factors for cognitive decline [22]. Research shows that older adults who maintain active social lives exhibit slower cognitive decline and have a reduced risk of developing Alzheimer's. Social activities that combine both physical and cognitive elements, such as dance and group sports, appear particularly effective [22]. Additionally, participation in community and group activities can provide emotional support, which plays a critical role in overall mental health and well-being [23].
Studies that examine the combined effects of cognitive and social activities suggest a synergistic benefit [23]. Engaging in both types of activities leads to greater protective effects against Alzheimer's than either activity alone [22]. Programs that integrate social interactions with cognitive challenges, such as book clubs, educational classes, and interactive games, are particularly effective [24]. These programs not only stimulate cognitive function but also ensure regular social contact, reinforcing the neural and social networks that are vital for cognitive health [25].

The evidence presented in this literature review highlights the significant role of cognitive and social engagement in reducing the risk and slowing the progression of Alzheimer's disease. These findings support the incorporation of cognitive and social activities into regular care routines for the elderly, particularly those at risk for or diagnosed with Alzheimer's disease [26]. Public health strategies aimed at increasing access to cognitive and social resources could potentially mitigate the impact of Alzheimer's on individuals and society [27]. Future research should continue to explore the mechanisms through which cognitive and social engagement affect Alzheimer's disease and identify specific activities that are most beneficial for this purpose [27].

DISCUSSION

Recent studies on Alzheimer's disease (AD) provide a comprehensive overview of factors that influence its risk, progression, and management. Research integrating genetic, lifestyle, and environmental factors offers a more holistic understanding of AD. For instance, studies showing the impact of cognitive and social engagement on reducing AD risk complement genetic studies that identify high-risk individuals. This suggests a multifaceted approach to AD prevention that incorporates both inherent risk factors and modifiable lifestyle choices. Additionally, advancements in neuroimaging have enhanced our understanding of the disease's progression, revealing how changes in brain structure and function correlate with symptom severity and cognitive decline.

The synthesis of these research findings has significant clinical implications for the treatment, management, and prevention of Alzheimer's disease. Early detection and personalized treatment plans are now more feasible, thanks to genetic screening and advanced imaging techniques. Lifestyle interventions, such as increased physical, cognitive, and social activity, have been validated as effective strategies for delaying AD onset and mitigating its progression, providing a non-pharmacological approach that can be integrated into patient care plans. Furthermore, the understanding of neuroplasticity and cognitive reserve in AD suggests that cognitive rehabilitation and mental exercises could be prescribed as part of routine management to help maintain cognitive function for as long as possible.

Despite significant advancements, there remain inconsistencies and gaps in Alzheimer's research. One major gap is the variability in how different populations respond to similar treatment and prevention strategies, suggesting a need for more culturally and genetically diverse research studies. Additionally, the exact mechanisms through which lifestyle factors influence AD progression are not fully understood, requiring further molecular and longitudinal studies. Another critical area needing exploration is the development of more effective biomarkers for early detection, particularly biomarkers that can be identified in non-invasive ways, such as through blood tests or digital monitoring tools.

Future research should focus on expanding the diversity of study populations to include underrepresented groups, which could help in understanding variations in AD prevalence and response to treatment across different ethnicities and socioeconomic statuses. Additionally, longitudinal studies that track lifestyle factors and their direct impact on AD progression are necessary to establish causative relationships and effective prevention strategies. Finally, there is a need for continued innovation in developing and validating non-invasive biomarkers that could facilitate earlier and more accurate diagnosis of AD, potentially leading to better outcomes through early intervention.

CONCLUSION

In conclusion, this literature review has highlighted several critical advancements in the understanding and management of Alzheimer's disease (AD). The pathophysiological insights gained over recent years have been substantial. The amyloid-beta (Aβ) hypothesis remains central to our understanding of AD pathogenesis, with significant evidence linking Aβ accumulation to neurodegenerative processes. Additionally, the role of tau protein hyperphosphorylation and the subsequent formation of neurofibrillary tangles (NFTs) have been recognised as crucial in disease progression, complementing the amyloid cascade hypothesis. Emerging research on neuroinflammation and the innate immune system, particularly the activation of microglia, offers new therapeutic avenues, further expanding our understanding of the disease mechanisms.
Genetic and biomarker discoveries have also made notable contributions to advancing the field. Genetic studies have identified several risk genes, such as APOE ε4, shedding light on individual susceptibility and potential targets for personalised medicine. Concurrently, advances in biomarker development, including cerebrospinal fluid (CSF) biomarkers and neuroimaging techniques like PET and MRI, have significantly improved early diagnosis and disease monitoring. These biomarkers facilitate the detection of AD at earlier stages, allowing for timely intervention and better tracking of disease progression.

Therapeutic developments have been a focal point of recent research. Disease-modifying therapies targeting Aβ, such as monoclonal antibodies like aducanumab, have shown promise, although their clinical efficacy and safety remain under scrutiny. Additionally, novel therapeutic approaches targeting tau pathology and neuroinflammation are in various stages of development, offering hope for more effective treatments. Non-pharmacological interventions, including lifestyle modifications and cognitive training, have also demonstrated benefits in slowing disease progression and improving the quality of life for patients with AD.

Innovations in clinical trial design have further enhanced the landscape of Alzheimer's research. Advances such as adaptive trial designs and the use of biomarkers for participant selection have improved the efficiency and success rates of clinical trials. Collaborative efforts and large-scale consortia have facilitated the sharing of data and resources, accelerating the pace of discovery and development of new therapies.

The significance of these findings lies in their potential to transform the management of Alzheimer's disease. Improved understanding of the disease mechanisms paves the way for more targeted and effective therapies. The identification of genetic and biomarker profiles enables early diagnosis and personalised treatment approaches. Moreover, innovative clinical trial methodologies promise to bring new therapies to patients more rapidly. Collectively, these advancements hold the promise of not only alleviating the burden of Alzheimer's disease on individuals and society but also ultimately achieving the goal of preventing and curing this devastating condition.

REFERENCES
